Research programme: HBD3 - Seattle Life SciencesAlternative Names: Beta defensin 3
Latest Information Update: 10 Sep 2010
At a glance
- Originator ZymoGenetics
- Developer Seattle Life Sciences
- Class Peptides
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Unspecified
Most Recent Events
- 10 Sep 2010 Discontinued for Undefined indication in USA (Parenteral)
- 05 May 2009 Early research in Undefined indication in USA (Parenteral)